InterVenn Blog

September 18, 2019
By Ling Shen Ley Hian Kiat Yee and Clinical Science Team

Happy Malaysia Day (16th September 2019) to all Malaysians! On behalf of InterVenn Biosciences (InterVenn), I wish all Malaysians unity, prosperity, and importantly, happiness and good health! On this auspicious day, I would like to take some time to reflect on InterVenn’s efforts and contributions to women’s healthcare in Malaysia, […]

August 7, 2019
By Dan Serie

It’s the late 2010’s, and genomic technologies have matured. The knowledge gleaned from yesterday’s basic research is beginning to make inroads into clinical practice, so it’s natural to seek out new frontiers. The central dogma of biology dictates that DNA stores our genetic information, RNA transcribes it for translation into […]

February 22, 2019
By Carlito Lebrilla

Our body is made up of proteins. Measuring the abundances of these proteins has been the primary goal of scientists because they give us a way of understanding diseases. More careful analysis of proteins reveals that no matter how similar proteins seem, they are not really the same. Proteins become […]

December 12, 2018
By Aldo Carrascoso

We envision a time when cancer is no longer a problem – and all disease a mere nuisance. In this time, disease is holistically understood enough for it to be controlled and manipulated to benefit all. We envision a place where previously unrelated disciplines intersect and “interdepend” in a singular […]

December 12, 2018
By Carlito Lebrilla Carolyn Bertozzi

Most proteomic endeavors have focused on identifying and quantifying expression levels of low abundance proteins. These queries are necessary but not sufficient, as the assessment of proteins is incomplete without simultaneously shining light on post-translational modifications (PTMs) and how they augment the proteome. PTMs decorate translated proteins in a dynamic […]

December 12, 2018
By Aldo Carrascoso

Funding to accelerate InterVenn’s development of its AI-driven mass spectrometry platform that measures glycoproteomic markers that have been strongly linked to tumor development and progression. Redwood City, Calif, December 12, 2018: — InterVenn BioSciences, a life sciences and technology company developing an AI-driven mass spectrometry platform, announced today an institutional […]

Hey! Just letting you know we use cookies. We use cookies to improve your browsing experience. By continuing to browse this site, you agree to our privacy policy and use of cookies.